Guido Magni
Bioinformatics & Systems Biology
Gensight
France
Biography
Guido Magni, M.D., Ph.D., is a Partner with Versant Ventures, based in Basel, Switzerland. Dr. Magni previously served as a Managing Director of EuroVentures, a Versant incubator, where he was involved with several biotech investments including Synosia Therapeutics AG, which was sold to Biotie Therapeutics AG, or Biotie, Flexion Therapeutics AG and Okairos AG, which was sold to GSK. Dr. Magni was previously Global Head of Medical Sciences in Roche, in the Global Drug Development department. During his twelve years in this position, Dr. Magni oversaw the development and the registration of a large number of new chemical and biological entities including Pegasys, Mabthera, Xeloda, Herceptin, Tamiflu and Tarceva. Dr. Magni currently serves on the board of Biotie, Piqur Therapeutics AG and AM Pharma B.V.. Dr. Magni has an M.D. degree from the University of Padua and a Ph.D. in neuropharmacology.
Research Interest
Bioinformatics & Systems Biology
